97 related articles for article (PubMed ID: 31272080)
1. Potentiated anti-tumor effects of BETi by MEKi in anaplastic thyroid cancer.
Zhu X; Park S; Lee WK; Cheng SY
Endocr Relat Cancer; 2019 Sep; 26(9):739-750. PubMed ID: 31272080
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of MEK Signaling Attenuates Cancer Stem Cell Activity in Anaplastic Thyroid Cancer.
Kimura T; Doolittle WKL; Kruhlak M; Zhao L; Hwang E; Zhu X; Tang B; Wolcott KM; Cheng SY
Thyroid; 2024 Apr; 34(4):484-495. PubMed ID: 38115586
[No Abstract] [Full Text] [Related]
3. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma.
Iyer PC; Dadu R; Gule-Monroe M; Busaidy NL; Ferrarotto R; Habra MA; Zafereo M; Williams MD; Gunn GB; Grosu H; Skinner HD; Sturgis EM; Gross N; Cabanillas ME
J Immunother Cancer; 2018 Jul; 6(1):68. PubMed ID: 29996921
[TBL] [Abstract][Full Text] [Related]
4. Bromodomain and Extraterminal Protein Inhibitor JQ1 Suppresses Thyroid Tumor Growth in a Mouse Model.
Zhu X; Enomoto K; Zhao L; Zhu YJ; Willingham MC; Meltzer P; Qi J; Cheng SY
Clin Cancer Res; 2017 Jan; 23(2):430-440. PubMed ID: 27440272
[TBL] [Abstract][Full Text] [Related]
5. The novel histone deacetylase inhibitor thailandepsin A inhibits anaplastic thyroid cancer growth.
Weinlander E; Somnay Y; Harrison AD; Wang C; Cheng YQ; Jaskula-Sztul R; Yu XM; Chen H
J Surg Res; 2014 Jul; 190(1):191-7. PubMed ID: 24679699
[TBL] [Abstract][Full Text] [Related]
6. Drug-induced inhibition of HMGA and EZH2 activity as a possible therapy for anaplastic thyroid carcinoma.
De Martino M; Pellecchia S; Decaussin-Petrucci M; Testa D; Meireles Da Costa N; Pallante P; Chieffi P; Fusco A; Esposito F
Cell Cycle; 2023; 22(23-24):2552-2565. PubMed ID: 38165007
[TBL] [Abstract][Full Text] [Related]
7. Targeting SIGLEC15 as an emerging immunotherapy for anaplastic thyroid cancer.
Bao L; Li Y; Hu X; Gong Y; Chen J; Huang P; Tan Z; Ge M; Pan Z
Int Immunopharmacol; 2024 May; 133():112102. PubMed ID: 38652971
[TBL] [Abstract][Full Text] [Related]
8. Anaplastic thyroid cancer spheroids as preclinical models to test therapeutics.
Hu J; Liu K; Ghosh C; Khaket TP; Shih H; Kebebew E
J Exp Clin Cancer Res; 2024 Mar; 43(1):85. PubMed ID: 38500204
[TBL] [Abstract][Full Text] [Related]
9. TRβ Agonism Induces Tumor Suppression and Enhances Drug Efficacy in Anaplastic Thyroid Cancer in Female Mice.
Gillis NE; Cozzens LM; Wilson ER; Smith NM; Tomczak JA; Bolf EL; Carr FE
Endocrinology; 2023 Aug; 164(10):. PubMed ID: 37702560
[TBL] [Abstract][Full Text] [Related]
10. BUB1/KIF14 complex promotes anaplastic thyroid carcinoma progression by inducing chromosome instability.
Jin T; Ding L; Chen J; Zou X; Xu T; Xuan Z; Wang S; Chen J; Wang W; Zhu C; Zhang Y; Huang P; Pan Z; Ge M
J Cell Mol Med; 2024 Apr; 28(7):e18182. PubMed ID: 38498903
[TBL] [Abstract][Full Text] [Related]
11. The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy.
Mi L; Liu J; Zhang Y; Su A; Tang M; Xing Z; He T; Wei T; Li Z; Wu W
Phytomedicine; 2024 Apr; 129():155670. PubMed ID: 38704915
[TBL] [Abstract][Full Text] [Related]
12. The m
Li P; Wang W; Zhou R; Ding Y; Li X
Clin Transl Med; 2023 Nov; 13(11):e1466. PubMed ID: 37983928
[TBL] [Abstract][Full Text] [Related]
13. A zebrafish xenotransplant model of anaplastic thyroid cancer to study tumor microenvironment and innate immune cell interactions in vivo.
Michael C; Mendonça-Gomes JM; DePaolo CW; Di Cristofano A; de Oliveira S
Endocr Relat Cancer; 2024 Jul; 31(7):. PubMed ID: 38657656
[TBL] [Abstract][Full Text] [Related]
14. Enhanced cytotoxic effect of camptothecin nanosponges in anaplastic thyroid cancer cells in vitro and in vivo on orthotopic xenograft tumors.
Gigliotti CL; Ferrara B; Occhipinti S; Boggio E; Barrera G; Pizzimenti S; Giovarelli M; Fantozzi R; Chiocchetti A; Argenziano M; Clemente N; Trotta F; Marchiò C; Annaratone L; Boldorini R; Dianzani U; Cavalli R; Dianzani C
Drug Deliv; 2017 Nov; 24(1):670-680. PubMed ID: 28368209
[TBL] [Abstract][Full Text] [Related]
15. Combined effects of octreotide and cisplatin on the proliferation of side population cells from anaplastic thyroid cancer cell lines.
Li Z; Jiang X; Chen P; Wu X; Duan A; Qin Y
Oncol Lett; 2018 Sep; 16(3):4033-4042. PubMed ID: 30128025
[TBL] [Abstract][Full Text] [Related]
16. dsRNAi-mediated silencing of PIAS2beta specifically kills anaplastic carcinomas by mitotic catastrophe.
Rodrigues JS; Chenlo M; Bravo SB; Perez-Romero S; Suarez-Fariña M; Sobrino T; Sanz-Pamplona R; González-Prieto R; Blanco Freire MN; Nogueiras R; López M; Fugazzola L; Cameselle-Teijeiro JM; Alvarez CV
Nat Commun; 2024 May; 15(1):3736. PubMed ID: 38744818
[TBL] [Abstract][Full Text] [Related]
17. Tissue Factor-Targeted ImmunoPET Imaging and Radioimmunotherapy of Anaplastic Thyroid Cancer.
Wei W; Liu Q; Jiang D; Zhao H; Kutyreff CJ; Engle JW; Liu J; Cai W
Adv Sci (Weinh); 2020 Jul; 7(13):1903595. PubMed ID: 32670751
[TBL] [Abstract][Full Text] [Related]
18. Augmentation of lenvatinib efficacy by topical treatment of
Kishikawa M; Inoue J; Hamamoto H; Kobayashi K; Asakage T; Inazawa J
Biochem Biophys Rep; 2021 Jul; 26():101009. PubMed ID: 34027135
[TBL] [Abstract][Full Text] [Related]
19. Nanotechnological Advancements for the Theranostic Intervention in Anaplastic Thyroid Cancer: Current Perspectives and Future Direction.
Uppalapati SS; Guha L; Kumar H; Mandoli A
Curr Cancer Drug Targets; 2024; 24(3):245-270. PubMed ID: 37424349
[TBL] [Abstract][Full Text] [Related]
20. Research progress of immunotherapy against anaplastic thyroid cancer.
Chen J; Xiao Z; Wu H
Front Oncol; 2024; 14():1365055. PubMed ID: 38595813
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
